Chase H P, Butler-Simon N, Garg S, McDuffie M, Hoops S L, O'Brien D
Barbara Davis Center for Childhood Diabetes, Department of Pediatrics, University of Colorado Health Sciences Center, Denver.
Diabetologia. 1990 Jul;33(7):444-6. doi: 10.1007/BF00404097.
Various agents have been tried in subjects with newly diagnosed Type 1 (insulin-dependent) diabetes mellitus in an attempt to preserve Beta-cell function. In this double-blind study, nicotinamide or placebo were given for one year to 35 children and adolescents with newly-diagnosed Type 1 diabetes. All subjects were within six weeks of diagnosis and were between the ages of 6 and 18 years. Nicotinamide, a poly-(ADP-ribose) synthetase inhibitor, was given in a dose of 100 mg/year of age up to a maximum of 1.5 g/day. There were no initial differences between the 17 control and the 18 test subjects in relation to mean age, sex distribution, or severity at onset. Mean insulin dosages and HbA1 values were similar for the two groups during the year of study. Fasting and glucagon-stimulated C-peptide levels were similar for the control and nicotinamide treated groups at the beginning and after 4 and 12 months. There were no differences in remission rates between the two groups. Nicotinamide, at this dosage, does not preserve residual insulin secretion in subjects with newly diagnosed Type 1 diabetes.
为了保留β细胞功能，人们对多种药物进行了试验，用于新诊断出的1型（胰岛素依赖型）糖尿病患者。在这项双盲研究中，对35名新诊断出1型糖尿病的儿童和青少年给予烟酰胺或安慰剂，为期一年。所有受试者在诊断后六周内，年龄在6至18岁之间。烟酰胺是一种聚（ADP - 核糖）合成酶抑制剂，给药剂量为每年100毫克/岁，最大剂量为1.5克/天。17名对照组和18名试验组受试者在平均年龄、性别分布或发病严重程度方面最初并无差异。在研究的一年中，两组的平均胰岛素剂量和糖化血红蛋白值相似。对照组和接受烟酰胺治疗的组在开始时、4个月和12个月后的空腹和胰高血糖素刺激的C肽水平相似。两组之间的缓解率没有差异。在此剂量下，烟酰胺并不能保留新诊断出的1型糖尿病患者的残余胰岛素分泌。
